Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $743.09M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.69M
Average 0.52M
AURA EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Aura Biosciences, Inc.NASDAQ: AURA
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -$0.5, compared with -$0.55 a year earlier. Trailing-twelve-month EPS (Basic) was -$1.77.
Context
- EPS (Basic) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 3 analysts of -$1.6 (+9.4%) for the fiscal year ending Dec 2026, a step up from the -0.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.5-25.0% QoQ
- Last fiscal yearDec 2025
- -$1.76-0.6% YoY
- LTMMar 2026
- -$1.77+6.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.1% | +20.2% | +11.1 pp |
| 1 year | -0.6% | +9.4% | +9.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (1.76) USD
- Year-over-year change
- -0.6%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.76) | -0.6% |
| FY2024 | 2024-12-31 | (1.75) | +9.3% |
| FY2023 | 2023-12-31 | (1.93) | +1.5% |
| FY2022 | 2022-12-31 | (1.96) | -24.1% |
| FY2021 | 2021-12-31 | (1.58) | — |
EPS (Basic) vs competitors
How AURA compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +6.8% is the 3rd highest of 11, against a peer median of -12.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$0.23 USD | -24.7% | — | |
| LTM Mar 2026 | -$1.1 USD | -23.6% | — | |
| FY2025 | -$1.19 USD | +5.6% | — | |
| LTM Mar 2026 | -$1.36 USD | -194.8% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$1.68 USD | -1088.2% | — |
| LTM Mar 2026 | -CHF 1.73 CHF | +27.0% | — | |
| LTM Mar 2026 | -$1.77 USD | +6.8% | — | |
| LTM Sep 2026 | -$2.65 USD | +10.2% | — | |
| LTM Mar 2026 | -$3.15 USD | -0.6% | — | |
| LTM Mar 2026 | -$3.5 USD | -45.2% | — | |
| LTM Mar 2026 | -$6.6 USD | +3.9% | — | |
| Peer median (excluding AURA) | — | -12.1% | — | |
Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.3M | 0 | 0 |
| Gross Profit | 0 | 0 | (1.3M) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 25.16M | 42.24M | 63.94M | 73.3M | 90.3M |
| Selling, General & Admin | 10.09M | 18.06M | 19.76M | 22.81M | 22.49M |
| Operating Expenses | 35.25M | 60.3M | 83.7M | 96.12M | 112.79M |
| Depreciation & Amortization | 831K | 1.18M | 1.3M | 1.22M | 1.13M |
| EBITDA | (34.41M) | (57.59M) | (74.98M) | (85.58M) | (104.95M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.25M) | (60.3M) | (84.99M) | (96.12M) | (112.79M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13K | 1.86M | 8.59M | 9.43M | 6.63M |
| Interest Expense | 13K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1K) | 1.53M | 8.72M | 9.31M | 6.71M |
| Income Before Tax | (35.25M) | (58.76M) | (76.27M) | (86.81M) | (106.08M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 137K | 112K | 108K |
| Net Income | (35.25M) | (58.76M) | (76.41M) | (86.92M) | (106.19M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.58) | (1.96) | (1.93) | (1.75) | (1.76) |
| EPS (Diluted) | (1.58) | (1.96) | (1.93) | (1.75) | (1.76) |
| Weighted Avg Shares | 29.21M | 29.94M | 39.62M | 49.65M | 60.34M |
| Weighted Avg Shares (Diluted) | 29.21M | 29.94M | 39.62M | 49.65M | 60.34M |
Aura Biosciences, Inc.
NASDAQ:AURA
Intrinsic Alpha fair value
Locked
Current Price
$7.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.